Oct 25, 2023 · Zymfentra (infliximab-dyyb) is a tumor necrosis factor (TNF) blocker that may be used to treat moderately to severely active Crohn’s disease or ulcerative colitis following …

Explore the importance of steady and stable serum drug levels. ZYMFENTRA gives patients increased flexibility and convenience through self-administration—for more freedom with less …

Discover ZYMFENTRA™, a proven treatment you can take at home.* ZYMFENTRA is for adults with moderate to severe ulcerative colitis or moderate to severe Crohn’s disease. It is given …

Detailed dosage guidelines and administration information for Zymfentra (infliximab-dyyb). Includes dose adjustments, warnings and precautions.

Discontinue infliximab if a patient develops a serious infection. Perform test for latent TB; if positive, start treatment for TB prior to starting infliximab. Monitor all patients for active TB …

Oct 2, 2024 · To help support your patients as they begin using ZYMFENTRA™, we’ve created a selection of downloadable resources along with a comprehensive Patient Starter Kit. An easy …

Zymfentra™ (infliximab-dyyb) – New drug approval • On October 23, 2023, Celltrion announced the FDA approval of Zymfentra (infliximab-dyyb), in adults for maintenance treatment of: — …

Apr 24, 2024 · Zymfentra (infliximab-dyyb) is a prescription medication that treats ulcerative colitis and Crohn’s disease in adults. It contains the same active ingredient as Remicade (infliximab), …

The pharmaceutical giant received approval from the U.S. Food and Drug Administration for its treatment for inflammatory bowel disease.

Drug Interactions. Concurrent use with immunosuppressive biologics used to treat UC and CD is not recommended due to risk of infection. Formation of CYP450 enzymes may be suppressed …